728 Enzalutamide impairs CD8 + T cell activation and does not alter the efficacy of AR-targeted vaccine in prostate cancer models
Year: 2026
Type: conference-abstract
Abstract: Background Androgen deprivation therapy (ADT) is a cornerstone treatment for prostate cancer (PCa), but over time, cancer cells become resistant, leading to disease progression. Second-generation androgen receptor pathway inhibitors (ARPIs), including agents that block the androgen receptor (AR), can be used in combination with ADT to mitigate therapeutic resistance. 1 2 Our previous studies showed that ADT increased AR expression in PCa cells, resulting in enhanced recognition by AR-specific CD8+ T cells.3 4 Further, our lab has demonstrated that AR-targeted vaccine, with ADT, produces greater anti-tumor efficacy than either treatment alone.3 Because AR blockade has also been reported to modulate CD8+ T cell activation and AR expression in PCa cells, we sought to determine whether AR blockade could further enhance the therapeutic efficacy of ADT in combination with AR-targeted vaccination.5–8Methods To assess the effects of AR blockade on immune cell function in vitro, CD8+ T cells, B cells, and dendritic cells (DCs) were isolated from OT-I or B6 mouse splenocytes and treated with enzalutamide. Immune cell activation and function were examined via flow cytometry and ELISA. Various human PCa cell lines were treated with enzalutamide and flutamide and evaluated for changes in AR expression via flow cytometry. A murine PCa model (Myc-CaP cells implanted in FVB mice) was used to assess whether enzalutamide alters immune recognition of prostate tumor cells and improves anti-tumor response when combined with AR-targeted vaccine.Results In vitro, enzalutamide reduced CD8+ T cell activation and function, as assessed by flow cytometry, and IFNy secretion measured via ELISA. Enzalutamide increased B cell activation and had no effect on DC activation. Further, enzalutamide decreased AR expression in PCa cell lines. In the Myc-CaP model, enzalutamide treatment delayed tumor growth regardless of co-administration with AR-targeted vaccine or vector control.Conclusions We propose that the lack of enhanced anti-tumor response observed with the combination of enzalutamide and AR-targeted vaccine is due to enzalutamide-mediated suppression of CD8 + T cell activation and reduced AR expression in PCa cells. Decreased AR expression may impair recognition of tumor cells by AR-specific CD8+ T cells generated through AR-targeted vaccination. Additionally, impairment of CD8+ T cell activation further limits cytotoxic immune responses. Based on these results, the addition of enzalutamide to AR-targeted immunotherapy and ADT may not improve anti-tumor responses compared to AR-targeted immunotherapy and ADT alone.References Azad AA, Petrylak DP, Iguchi T, Shore ND, Villers A, Gomez-Veiga F, et al. Enzalutamide and prostate-specific antigen levels in metastatic prostate cancer: a secondary analysis of the ARCHES randomized clinical trial. JAMA Netw Open. 2025;8:e258751. https://doi.org/10.1001/jamanetworkopen.2025.8751Shore ND, Luz M de A, Giorgi UD, Gleave M, Gotto GT, Pieczonka CM, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. New England Journal of Medicine Massachusetts Medical Society 2026;394:563–75. https://doi.org/10.1056/NEJMoa2510310Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, et al. Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T Cells. Cancer Immunology Research 2017;5:1074–85. https://doi.org/10.1158/2326-6066.CIR-16-0390Olson BM, McNeel DG. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother. 2011;60:781–92. https://doi.org/10.1007/s00262-011-0987-5Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci Transl Med. 2016;8:333ra47-333ra47. https://doi.org/10.1126/scitranslmed.aad5659Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg L-O, Ziegler P, et al. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells. J Cell Biochem. 2019;120:16711–22. https://doi.org/10.1002/jcb.28929Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 2022;606:791–6. https://doi.org/10.1038/s41586-022-04522-6Siciliano T, Simons IH, Beier A-MK, Ebersbach C, Aksoy C, Seed RI, et al. A systematic comparison of antiandrogens identifies androgen receptor protein stability as an indicator for treatment response. Life 2021;11:874. https://doi.org/10.3390/life11090874.
Institution: University of Wisconsin–Madison
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225308483
